The suppliers of two new anti-VEGF therapies recently cleared in the US that work to reduce macular disease treatment burdens are seeking approval to list the treatments on the Australian Pharmaceutical Benefits Scheme (PBS).
Read More
Roche’s faricimab meets primary endpoint in DME trial
Swiss drug giant Roche is poised to pursue regulatory clearance for its new faricimab antibody for diabetic macular edema (DME) after it produced a similar effect to Eylea in twin clinical trials, but with half the dosing regimen in several patients.
Read More
Read More
Clinical trial results reinforce potential new treatment for DME
Novartis has announced positive findings from its the Phase 3 trial assessing the efficacy and safety of Beovu (brolucizumab) to treat diabetic macular edema (DME).
Read More
Read More
Opthea progresses DME trials despite COVID-19 disruption
Results are imminent in biopharmaceutical company Opthea’s latest clinical trial evaluating the safety and efficacy of its lead drug candidate with Eylea in diabetic macular edema (DME) patients.
Read More
Read More
AI predicts treatment outcome for diabetic vision loss
A new approach that uses an algorithm to analyse retinal images could help practitioners select the best treatment for patients with vision loss from diabetic macular edema.
Read More
Read More